NASDAQ:HARP Harpoon Therapeutics (HARP) Stock Price, News & Analysis → Move Your Money Before May 1 (From Stansberry Research) (Ad) Free HARP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$23.01▼$23.0150-Day Range$22.34▼$23.0152-Week Range$3.11▼$23.21VolumeN/AAverage Volume1.52 million shsMarket Capitalization$389.61 millionP/E RatioN/ADividend YieldN/APrice Target$27.25 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainability Get Harpoon Therapeutics alerts: Email Address Harpoon Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside18.4% Upside$27.25 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.61Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$492.14 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.49) to ($4.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.24 out of 5 starsMedical Sector590th out of 908 stocksBiotechnology Industry8th out of 22 stocks 2.2 Analyst's Opinion Consensus RatingHarpoon Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageHarpoon Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for HARP. Previous Next 0.0 Dividend Strength Dividend YieldHarpoon Therapeutics does not currently pay a dividend.Dividend GrowthHarpoon Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHarpoon Therapeutics has received a 76.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Harpoon Therapeutics is -0.61. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Harpoon Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for HARP on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harpoon Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $492,135,715.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders17.00% of the stock of Harpoon Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.01% of the stock of Harpoon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Harpoon Therapeutics are expected to decrease in the coming year, from ($1.49) to ($4.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harpoon Therapeutics is -2.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harpoon Therapeutics is -2.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarpoon Therapeutics has a P/B Ratio of 14.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Harpoon Therapeutics Stock (NASDAQ:HARP)Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company at the forefront of revolutionizing cancer treatment and other diseases. The company is developing a novel T-cell engagers class to use the body's immune system to fight infection. Harpoon currently has several products in various stages of clinical trials, such as HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors and HPN217, which is in Phase I/II clinical trials for the treatment of multiple myeloma. Shares of Harpoon have skyrocketed following the release of data from its Phase 1 clinical trial for HPN217, a single-agent candidate for pretreated patients with relapsed/refractory multiple myeloma (RRMM). The data showed clinical activity and a "tolerable safety profile," with low-grade CRS observed in 29% of patients following the first or second doses of the drug and no incidents of "Grade 3 or higher CRS." Analysts have a consensus price target of $8.75 on the stock, suggesting over 85% upside potential. Harpoon has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products incorporating TriTAC platform technology and soluble T cell receptors. In addition, the company has a preclinical stage product, HPN601, for treating multiple solid tumor indications.Written by Jeffrey Neal JohnsonRead More Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. HARP Stock News HeadlinesApril 25, 2024 | msn.comMerck raises 2024 profit forecast on surging sales of cancer drug KeytrudaMarch 16, 2024 | finance.yahoo.comHARP Sep 2024 20.000 putApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? March 16, 2024 | finance.yahoo.comHARP Apr 2024 20.000 putMarch 13, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Merck & Company (MRK)March 12, 2024 | msn.comMerck completes acquisition of Harpoon TherapeuticsMarch 7, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), Brainsway (BWAY) and Wave Life Sciences (WVE)March 6, 2024 | msn.comHarpoon Therapeutics ticks higher amid Nasdaq delisting notice for sale to MerckApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? February 27, 2024 | msn.comCitigroup Downgrades Harpoon Therapeutics (HARP)February 26, 2024 | markets.businessinsider.comAnalyst Scoreboard: 4 Ratings For Harpoon TherapeuticsFebruary 24, 2024 | realmoney.thestreet.comHarpoon Therapeutics just downgraded at Citi, here's whyFebruary 23, 2024 | usnews.comFate of US Aid to Ukraine Package Discussed on Taiwan Trip, Lawmakers SayFebruary 23, 2024 | msn.comMerck wins EU backing for Keytruda use in resectable lung cancerFebruary 23, 2024 | finance.yahoo.comHARPOON THERAPEUTICS (5HTA.BE)February 23, 2024 | finance.yahoo.comHarpoon Therapeutics Inc. (5HTA.SG)February 22, 2024 | benzinga.comStock (HARP), Short Interest ReportFebruary 13, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Immunovant (IMVT), 4D Molecular Therapeutics (FDMT)February 1, 2024 | msn.comMerck Hasn't Even Closed Its Last Buyout, But It's Already Hunting For The Next DealJanuary 30, 2024 | finance.yahoo.comWhile private equity firms own 20% of Harpoon Therapeutics, Inc. (NASDAQ:HARP), retail investors are its largest shareholders with 36% ownershipJanuary 19, 2024 | finanznachrichten.deArix Bioscience PLC: Financial update on Harpoon Therapeutics acquisition by Merck (MSD)January 16, 2024 | markets.businessinsider.comPeeling Back The Layers: Exploring Harpoon Therapeutics Through Analyst InsightsJanuary 11, 2024 | baystreet.caMerck Stock Gains After Snatching Harpoon TherapeuticsJanuary 9, 2024 | msn.comMerck Buys Harpoon Therapeutics To Expand Its Oncology PortfolioJanuary 9, 2024 | finance.yahoo.comMerck (MRK) to Strengthen Cancer Pipeline With Harpoon BuyoutJanuary 8, 2024 | investorplace.comWhy Is Harpoon Therapeutics (HARP) Stock Up 111% Today?January 8, 2024 | markets.businessinsider.comMerck In Talks To Acquire Harpoon Therapeutics: ReportsSee More Headlines Receive HARP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harpoon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2023Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:HARP CUSIPN/A CIK1708493 Webwww.harpoontx.com Phone(650) 443-7400FaxN/AEmployees53Year FoundedN/APrice Target and Rating Average Stock Price Target$27.25 High Stock Price Target$40.00 Low Stock Price Target$23.00 Potential Upside/Downside+18.4%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($8.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,730,000.00 Net Margins-81.68% Pretax Margin-81.67% Return on Equity-893.55% Return on Assets-45.98% Debt Debt-to-Equity RatioN/A Current Ratio1.89 Quick Ratio1.89 Sales & Book Value Annual Sales$37.34 million Price / Sales10.43 Cash FlowN/A Price / Cash FlowN/A Book Value$1.63 per share Price / Book14.12Miscellaneous Outstanding Shares16,932,000Free Float14,054,000Market Cap$389.61 million OptionableOptionable Beta2.11 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMs. Julie M. Eastland M.B.A. (Age 60)President, CEO, Secretary & Director Comp: $910.77kDr. Luke N. Walker M.D. (Age 52)Chief Medical Officer Comp: $424.43kMr. Michael Eric Faerm (Age 57)Interim Chief Financial Officer Dr. Chatan Charan Ph.D.Senior Vice President of Product Development, Technical & Manufacturing OperationsMr. James B. Bucher J.D. (Age 58)Chief Legal Officer Ms. Wendy ChangChief People OfficerDr. Banmeet Anand Ph.D.Senior Vice President of Translational MedicineMr. Haibo WangSenior Vice President of Business DevelopmentMore ExecutivesKey CompetitorsNektar TherapeuticsNASDAQ:NKTRNGM BiopharmaceuticalsNASDAQ:NGMKinnate BiopharmaNASDAQ:KNTEMersana TherapeuticsNASDAQ:MRSNHeron TherapeuticsNASDAQ:HRTXView All CompetitorsInsiders & InstitutionsMerck & Co., Inc.Bought 21,397,205 shares on 3/11/2024Total: $492.14 M ($23.00/share)Blackstone Inc.Bought 815,000 shares on 2/15/2024Ownership: 4.813%New Leaf Venture Partners L.L.C.Bought 1,543,500 shares on 2/14/2024Ownership: 10.982%Commodore Capital LPBought 1,500,000 shares on 2/14/2024Ownership: 8.859%Franklin Resources Inc.Bought 1,360,041 shares on 2/9/2024Ownership: 8.815%View All Insider TransactionsView All Institutional Transactions HARP Stock Analysis - Frequently Asked Questions Should I buy or sell Harpoon Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" HARP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HARP, but not buy additional shares or sell existing shares. View HARP analyst ratings or view top-rated stocks. What is Harpoon Therapeutics' stock price target for 2024? 6 Wall Street research analysts have issued 12-month target prices for Harpoon Therapeutics' shares. Their HARP share price targets range from $23.00 to $40.00. On average, they expect the company's share price to reach $27.25 in the next twelve months. This suggests a possible upside of 18.4% from the stock's current price. View analysts price targets for HARP or view top-rated stocks among Wall Street analysts. How were Harpoon Therapeutics' earnings last quarter? Harpoon Therapeutics, Inc. (NASDAQ:HARP) released its quarterly earnings data on Monday, March, 27th. The company reported ($5.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.70) by $0.80. The company had revenue of $4.09 million for the quarter, compared to the consensus estimate of $11.06 million. Harpoon Therapeutics had a negative trailing twelve-month return on equity of 893.55% and a negative net margin of 81.68%. What ETF holds Harpoon Therapeutics' stock? AltShares Merger Arbitrage ETF holds 52,182 shares of HARP stock, representing 1.96% of its portfolio. When did Harpoon Therapeutics' stock split? Harpoon Therapeutics's stock reverse split on Tuesday, September 5th 2023. The 1-10 reverse split was announced on Tuesday, September 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Gerald McMahon's approval rating as Harpoon Therapeutics' CEO? 5 employees have rated Harpoon Therapeutics Chief Executive Officer Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among the company's employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Harpoon Therapeutics to a friend. What other stocks do shareholders of Harpoon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD). When did Harpoon Therapeutics IPO? Harpoon Therapeutics (HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners acted as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers. This page (NASDAQ:HARP) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harpoon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.